glp 1 and pancreatic cancer Favorable Effects of GLP-1 Receptor Agonist against β-Cell Glucose Toxicity the Development of Arteriosclerosis: “The Earlier, the Better” in Therapy with Incretin-Based Medicine glp 1 pancreatic cancer GLP-1

Modelstudies naar peptide-eiwitinteractie in celkweeksystemen, waarbij prolinerijke motieven als bindingsmotief dienen

The authors noted that results from more recent studies were less positive than those from earlier studies, and concluded that routine clinical use of ALCAR to treat dementia signs and symptoms was not justified [15]

After an average of 28.6 months, the incidence of major cardiovascular events was 31% lower in those given colchicine relative to those given placebo

Given the impact of type 2 diabetes on cardiovascular and neurological diseases, GLP-1 agonists and SGLT2 inhibitors represent a valid pharmacological tool for improving cardiometabolic profile and diabetes-related cognitive impairment